In summary, our 12‐gene DTG‐S signature displays excellent predictive values for DFS and for a pathological response to anthracycline‐and/or taxane‐based chemotherapy in HER2‐negative breast cancer. This evidence concerns the gene ERBB2 and breast cancer.